Pharmaceutical composition for stabilising atherosclerotic plaques

A pharmaceutical composition for stabilising atherosclerotic plaques, preventing new plaques forming and resolving existing atherosclerotic plaques comprising L-lysine or salt, ester or complex thereof, L-magnesium ascorbate or L-ascorbic acid or a salt or ester thereof, α-tocopherol or an isomer or derivative thereof, lycopene or related carotenoid other than β-carotene, coenzyme Q10, bioflavonoid or complex, together with a pharmaceutically acceptable carrier therefor.

A pharmaceutical composition for stabilising atherosclerotic plaques, preventing new plaques forming and resolving existing atherosclerotic plaques comprising from 20 to 60% by weight of amino acid or salt or ester thereof, from 20 to 60% by weight ascorbic acid or salt or ester thereof or 20 to 60% by weight magnesium ascorbate, from 5 to 20% by weight of tocopherol or isomer or ester thereof, from 0.2 to 1% by weight of lycopene or ester thereof or a related carotenoid other than β-carotene and from 4 to 12% by weight of flavonoid or complex thereof, and if magnesium ascorbate is not present, 2 to 6% by weight of a magnesium compound.

A pharmaceutical composition for stabilising atherosclerotic plaques, preventing new plaques forming and resolving existing atherosclerotic plaques in unit dosage form, said composition comprising from 150 to 450 mg d,l-α tocopheryl acetate, from 1.5 to 8.0 mg lycopene, from 2000 to 4000 mg L-lysine, from 1600 to 5000 mg magnesium ascorbate and from 300 to 900 mg bioflavonoid mixture.

A method of treating thromboembolic disease comprising administering to a patient in need thereof a pharmaceutical formulation comprising lycopene or a related carotenoid other than β-carotene, at least one flavonoid, an amino acid or derivative or precursor thereof, magnesium, ascorbate and tocopherol or a derivative, precursor or isomer thereof.